Search Results for “antibody” – Page 8 – media

GSK’s investigational BCMA antibody-drug conjugate receives Breakthrough Therapy Designation from US FDA for relapsed and refractory multiple myeloma

In October, the European Medicines Agency (EMA) granted PRIME designation to GSK2857916 for the treatment of relapsed and refractory multiple myeloma patients whose prior therapy included a proteasome inhibitor, an immunomodulatory agent and an anti-CD38 antibody. GSK2857916 is an anti B-cell maturation agent (BCMA) monoclonal antibody-drug conjugate.
- Source: gsk
- 556
- November 3, 2017
inhibitor multiple myeloma New Approvals refractory relapsed
MRC links with UCB in antibody initiative

The Medical Research Council (MRC) and UCB have launched a new scheme designed to help accelerate work on the development of antibody-based therapeutics.
- Source: pharmatimes
- 854
- August 4, 2017
antibody Company Insight Researches
Commercial raw liquid and formulation workshop of Altruist Biologics ADC has been officially put into operation

On November 15, 2024, Altruist Biologicstech, a leading domestic biopharmaceutical CDMO company, announced that its antibody conjugated drug (ADC) raw liquid and formulation production workshop (M3) located at its Hangzhou production base has officially started production! Becoming one of the few companies in China that can provide one-stop services from antibody and antibody conjugate drug stock solutions to formulations. This powerful production capacity will be able to meet the growing demand for ADC drugs in the market, accelerate the process of partner product launch, and enhance competitiveness. On that day, Altruist Biologicstech Hangzhou Base welcomed a visiting delegation composed of outstanding founders and executives from the domestic biopharmaceutical industry, who visited the ADC commercial raw material and preparation workshop, as well as four 20000 liter antibody raw material factories and preparation factories. The delegation expressed high interest and appreciation for the design layout, advanced hardware facilities, and automated production lines ...
- Source: drugdu
- 45
- November 20, 2024
Pumis announces equity acquisition agreement with BioNTech

According to the terms of the agreement, BioNTech will acquire 100% of Pumis’ issued share capital for a prepayment of $800 million (approximately RMB 5.781 billion) (subject to customary adjustment of the acquisition price), primarily in cash and a portion of American Depositary Shares (ADS). In addition, BioNTech will pay an additional milestone payment of up to $150 million (approximately RMB 1.084 billion) when Pumis meets the milestone conditions agreed upon by both parties. The transaction is expected to be completed in the first quarter of 2025, subject to customary delivery conditions and regulatory approvals. After the completion of this transaction, BioNTech will acquire full rights to the Pumis candidate drug pipeline and its bispecific antibody drug development platform, further expanding its business scope in China; Pumis Zhuhai will serve as the BioNTech China R&D center to conduct related R&D research; The Pumis Nantong production base, which meets international standards, ...
- Source: drugdu
- 43
- November 19, 2024
Haoyuan Pharmaceutical’s stock price rose by more than 150%

The cold winter of CXO has lasted for three full years since the second half of 2021. From industry leaders to emerging pharmaceutical companies, everyone has felt the chill. However, since the second half of 2024, the entire industry has shown some signs of recovery. Against the backdrop of interest rate cuts in Europe and the United States, the situation in the pharmaceutical investment and financing market has reversed, orders from many listed companies have begun to grow, and the industry turning point is about to come. Haoyuan Pharmaceutical is one of the first CXO companies to feel the warmth. Since the end of August, the stock price has risen from a low of 18.49 yuan/share to a high of 46.52 yuan/share, an increase of more than 150%. Haoyuan Pharmaceutical stock price trend Image source: Oriental Fortune What is the secret of Haoyuan Pharmaceutical behind the fluctuations in stock prices? ...
- Source: drugdu
- 28
- November 19, 2024
【EXPERT Q&A】What are the requirements for naming in vitro diagnostic reagents?

Drugdu.com expert’s response: The naming of in vitro diagnostic reagents must follow a series of clear requirements to ensure the standardization, accuracy, and ease of understanding of the names. These requirements mainly include the following points: Ⅰ. Naming Structure The product name of in vitro diagnostic reagents typically consists of three parts: Name of the Substance Being Tested: This is the target substance that the reagent detects, and the name should accurately reflect the characteristics of the substance being tested. Purpose: Describes the purpose of the reagent, such as “assay kit,” “quality control material,” etc. This part helps users understand the specific application of the reagent. Method or Principle: Explains the method or principle of the reagent’s detection, such as “magnetic bead-based chemiluminescent immunoassay,” “fluorescent PCR method,” “fluorescent in situ hybridization,” etc. This information is usually listed in parentheses to provide additional technical details. Ⅱ. Specific Naming Rules Quantitative vs. Qualitative ...
- Source: drugdu
- 37
- November 18, 2024
Global product revenue exceeds 7 billion yuan! BeiGene’s third quarter report is released

On the evening of November 12, BeiGene released its 2024 third quarter US stock performance report and A-share main financial data announcement. In the third quarter, BeiGene continued its strong growth momentum, achieving revenue of 7.139 billion yuan, a year-on-year increase of 26.9%. Global product revenue reached 7.079 billion yuan, a year-on-year increase of 65.1%. In the first three quarters of 2024, BeiGene’s total operating revenue reached 19.136 billion yuan, a year-on-year increase of 48.6%. Products continued to increase in volume at a high speed, with product revenue of 18.986 billion yuan in the first three quarters, a year-on-year increase of 72.9%. Whether it is total revenue or product revenue, the first three quarters have exceeded last year’s full-year revenue of 17.423 billion yuan, and the performance is very eye-catching. The US stock financial report shows that BeiGene’s financial situation continues to improve, with total revenue of US$1.002 billion this ...
- Source: drugdu
- 36
- November 18, 2024
Global product revenue exceeds 7 billion yuan! BeiGene’s third quarter report is released

On the evening of November 12, BeiGene released its third quarter 2024 U.S. stock performance report and A-share main financial data announcement. In the third quarter, BeiGene continued its strong growth momentum, achieving revenue of 7.139 billion yuan, a year-on-year increase of 26.9%. Global product revenue reached 7.079 billion yuan, a year-on-year increase of 65.1%. The overall performance is eye-catching . In the first three quarters of 2024, BeiGene’s total operating revenue reached 19.136 billion yuan, a year-on-year increase of 48.6%. Products continue to increase in volume at a high speed, with product revenue of 18.986 billion yuan in the first three quarters, a year-on-year increase of 72.9%. Whether it is total revenue or product revenue, the first three quarters have exceeded last year’s full-year revenue of 17.423 billion yuan, and the performance is very eye-catching. According to the U.S. stock financial report, BeiGene’s financial situation continues to improve, with ...
- Source: drugdu
- 46
- November 16, 2024
15%! AstraZeneca’s revenue in China exceeded 35 billion in the first nine months

AstraZeneca disclosed its financial report for the first three quarters of 2024 on November 12. The company’s revenue was 39.182 billion US dollars, a year-on-year increase of 19%; of which product revenue was 37.576 billion US dollars, a year-on-year increase of 19%. AstraZeneca raised its full-year performance guidance for 2024 in the announcement, and it is expected that both full-year revenue and core earnings per share will achieve high-ten-digit percentage growth, which was previously expected to be in the mid-ten digits. From the perspective of regional distribution, the Chinese market has undoubtedly become an important engine for AstraZeneca’s performance growth. In the first three quarters of 2024, AstraZeneca’s revenue in China reached more than 5 billion US dollars (equivalent to more than 35 billion yuan in RMB), accounting for about 13% of its global market share, becoming an important part of AstraZeneca’s global business. Many people may have no idea ...
- Source: drugdu
- 45
- November 15, 2024
Four innovative pharmaceutical companies have completed a new round of financing! 3 from China

According to the Instant Drug Database, last week (November 4th to November 10th), at least four emerging companies dedicated to innovative drug research and development worldwide announced the completion of a new round of financing, including three Chinese companies. These emerging companies that have gained favor in the capital market are developing drug types such as gene therapy drugs, iPSC cell therapy drugs, peptide vaccines, and antibody conjugated drugs (ADCs) with dual payloads. Kanglin Biotechnology Financing round: Series A Financing amount: 150 million yuan On November 8th, Kanglin Biotechnology (Hangzhou) Co., Ltd. (referred to as “Kanglin Biotechnology”) announced the completion of a 150 million yuan Series A financing, jointly invested by Zhejiang Province’s “4+1” Biomedical and High end Device Industry Fund and old shareholder Zhejiang Miyin Investment Management Co., Ltd. Kanglin Biology was founded in 2015, focusing on the R&D and commercialization of innovative drugs for gene therapy, targeting diseases ...
- Source: drugdu
- 51
- November 13, 2024

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.